Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) Completed Phase 2 Trials for Flu caused by Influenza Prevention

CompletedPrevention2 IdentifierTitleDrugs
NCT01974895Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age
NCT02918006A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine
NCT02553343A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older
NCT00283283Half vs Full Dose Influenza Vaccine
NCT00253734Immunogenicity and Safety of Different Doses of FluzoneĀ® Influenza
NCT00504231Intradermal Influenza Vaccine Study in Elders
NCT00524940Trial to Describe the Safety and Immunogenicity of FluzoneĀ®
NCT00623181Study to Determine a Preference for Fluzone Vaccine Given Intradermally (ID) and Intramuscularly (IM) in Healthy Adults
NCT00905125Influenza Vaccine in Pregnant Women
NCT00936468Safety, Tolerability and Immunogenicity of FluzoneĀ® With and Without JVRS-100 in Elderly Subjects
NCT00988143A Study of Influenza Virus Vaccines in Children and Adults
NCT01011049Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM
NCT011732112010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant Women
NCT01258595A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age